These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17614733)

  • 21. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
    Schmidt-Erfurth U; Miller JW; Sickenberg M; Laqua H; Barbazetto I; Gragoudas ES; Zografos L; Piguet B; Pournaras CJ; Donati G; Lane AM; Birngruber R; van den Berg H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
    Arch Ophthalmol; 1999 Sep; 117(9):1177-87. PubMed ID: 10496389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Photodynamic therapy for polypoidal choroidal vasculopathy.
    Nowak-Sliwinska P; van den Bergh H; Sickenberg M; Koh AH
    Prog Retin Eye Res; 2013 Nov; 37():182-99. PubMed ID: 24140257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retinal angiomatous proliferation treated with a combination of intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin.
    Mantel I; Ambresin A; Zografos L
    Eur J Ophthalmol; 2006; 16(5):705-10. PubMed ID: 17061221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Photodynamic therapy with verteporfin in occult choroidal neovascularization in age-related macular degeneration].
    Kürzinger GR; Stender B; Lang GK; Lang GE
    Klin Monbl Augenheilkd; 2010 Jun; 227(6):501-6. PubMed ID: 20349399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.
    Parmeggiani F; Gemmati D; Costagliola C; Sebastiani A; Incorvaia C
    Pharmacogenomics; 2009 Jan; 10(1):81-95. PubMed ID: 19102718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intravitreal ranibizumab in combination with verteporfin photodynamic therapy in neovascular macular degeneration].
    Soucek P; Soucková I
    Cesk Slov Oftalmol; 2008 Jul; 64(4):135-40. PubMed ID: 18780651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration.
    Wickens J; Blinder KJ
    Drug Saf; 2006; 29(3):189-99. PubMed ID: 16524319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2.
    Renno RZ; Terada Y; Haddadin MJ; Michaud NA; Gragoudas ES; Miller JW
    Arch Ophthalmol; 2004 Jul; 122(7):1002-11. PubMed ID: 15249365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne), in the CAM model.
    Debefve E; Pegaz B; van den Bergh H; Wagnières G; Lange N; Ballini JP
    Angiogenesis; 2008; 11(3):235-43. PubMed ID: 18324477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients].
    Chen YX; Ge J; Yan M; Jin CJ; Zhang MX; Dong FT; Lu F; Zhang CF; Zhao JL
    Zhonghua Yan Ke Za Zhi; 2007 Mar; 43(3):198-205. PubMed ID: 17605900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Photodynamic-induced vascular damage of the chick chorioallantoic membrane model using perylenequinones.
    Chin W; Lau W; Lay SL; Wei KK; Olivo M
    Int J Oncol; 2004 Oct; 25(4):887-91. PubMed ID: 15375536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced photodynamic activity of hypericin by penetration enhancer N-methyl pyrrolidone formulations in the chick chorioallantoic membrane model.
    Saw CL; Heng PW; Chin WW; Soo KC; Olivo M
    Cancer Lett; 2006 Jul; 238(1):104-10. PubMed ID: 16054752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes.
    Berdugo M; Bejjani RA; Valamanesh F; Savoldelli M; Jeanny JC; Blanc D; Ficheux H; Scherz A; Salomon Y; BenEzra D; Behar-Cohen F
    Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1633-44. PubMed ID: 18385085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous two-photon excitation of photofrin in relation to photodynamic therapy.
    Karotki A; Khurana M; Lepock JR; Wilson BC
    Photochem Photobiol; 2006; 82(2):443-52. PubMed ID: 16613497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy.
    Ghazi NG; Jabbour NM; De La Cruz ZC; Green WR
    Retina; 2001; 21(5):478-86. PubMed ID: 11642377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo damage to chorioallantoic membrane blood vessels by porphycene-induced photodynamic therapy.
    Gottfried V; Davidi R; Averguj C; Kimel S
    J Photochem Photobiol B; 1995 Oct; 30(2-3):115-21. PubMed ID: 8558365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV.
    Lange N; Ballini JP; Wagnieres G; van den Bergh H
    Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):38-46. PubMed ID: 11133846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment.
    Saito M; Iida T; Nagayama D
    Br J Ophthalmol; 2008 Dec; 92(12):1642-7. PubMed ID: 18782798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.